Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Semaglutide in Healthy Chinese Subjects
NCT03288740Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2017
- Primary completion
- Jul 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of semaglutide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the semaglutide plasma concentration time curve at steady state. Started Sep 2017; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03288740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03288740.